Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jun 15;15(1):10.
doi: 10.1186/s12263-020-00669-x.

Genetic risk prediction of the plasma triglyceride response to independent supplementations with eicosapentaenoic and docosahexaenoic acids: the ComparED Study

Bastien Vallée Marcotte  1 , Janie Allaire  1 , Frédéric Guénard  1 , Juan de Toro-Martín  1 , Patrick Couture  1   2 , Benoît Lamarche  1 , Marie-Claude Vohl  3
Affiliations

Genetic risk prediction of the plasma triglyceride response to independent supplementations with eicosapentaenoic and docosahexaenoic acids: the ComparED Study

Bastien Vallée Marcotte et al. Genes Nutr. .

Abstract

Background: We previously built a genetic risk score (GRS) highly predictive of the plasma triglyceride (TG) response to an omega-3 fatty acid (n-3 FA) supplementation from marine sources. The objective of the present study was to test the potential of this GRS to predict the plasma TG responsiveness to supplementation with either eicosapentaenoic (EPA) or docosahexaenoic (DHA) acids in the Comparing EPA to DHA (ComparED) Study.

Methods: The ComparED Study is a double-blind, controlled, crossover trial, with participants randomized to three supplemented phases of 10 weeks each: (1) 2.7 g/day of DHA, (2) 2.7 g/day of EPA, and (3) 3 g/day of corn oil (control), separated by 9-week washouts. The 31 SNPs used to build the previous GRS were genotyped in 122 participants of the ComparED Study using TaqMan technology. The GRS for each participant was computed by summing the number of rare alleles. Ordinal and binary logistic models, adjusted for age, sex, and body mass index, were used to calculate the ability of the GRS to predict TG responsiveness.

Results: The GRS predicted TG responsiveness to EPA supplementation (p = 0.006), and a trend was observed for DHA supplementation (p = 0.08). The exclusion of participants with neutral TG responsiveness clarified the association patterns and the predictive capability of the GRS (EPA, p = 0.0003, DHA p = 0.01).

Conclusion: Results of the present study suggest that the constructed GRS is a good predictor of the plasma TG response to supplementation with either DHA or EPA.

Trial registration: ClinicalTrials.gov, NCT01810003. The study protocol was registered on March 4, 2013.

Keywords: DHA; EPA; Genetic risk score; Nutrigenetics; Omega-3 fatty acids; Plasma triglyceride levels.

PubMed Disclaimer

Conflict of interest statement

BVM and JA received a studentship from the Fonds de recherche du Québec—Santé (FRQS). JA received a studentship from CIHR. JDTM received a postdoctoral fellowship from the FRQS. PC received a scholarship from FRQS. MCV is Tier 1 Canada Research Chair in Genomics Applied to Nutrition and Metabolic Health. Other authors have no conflict of interest to declare.

Figures

Fig. 1
Fig. 1
Predicted probability of classification into each subgroup of triglyceride responsiveness following EPA or DHA supplementation. The predicted probability of classification into each of the subgroups of triglyceride responsiveness (R/NR/AR) according to the genetic risk score is represented by curves. Predicted probabilities were assessed by ordinal (a) and binary (b) logistic regression, adjusted for age, sex, and body mass index. The observed density distribution of participants according to their genetic risk score is illustrated by horizontal violin plots, which are independent of the y-axis. a All the participants are included in the genetic risk model: (1) responders (R), (2) non-responders (NR), and (3) adverse responders (AR). b Only R (upper violin) and AR (lower violin) participants are included in the genetic risk model (NR participants are excluded). The 95% confidence intervals are highlighted in blue
See this image and copyright information in PMC

References

    1. Pejic RN, Lee DT. Hypertriglyceridemia. J Am Board Fam Med. 2006;19:310–316. doi: 10.3122/jabfm.19.3.310. - DOI - PubMed
    1. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Sacks F, Murad MH, Stalenhoef AF. Endocrine s. Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2012;97:2969–2989. doi: 10.1210/jc.2011-3213. - DOI - PMC - PubMed
    1. Berglund L, Brunzell JD, Goldberg AC, Goldberg IJ, Stalenhoef A. Treatment options for hypertriglyceridemia: from risk reduction to pancreatitis. Best Pract Res Clin Endocrinol Metab. 2014;28:423–437. doi: 10.1016/j.beem.2013.10.002. - DOI - PMC - PubMed
    1. Ito MK. Long-chain omega-3 fatty acids, fibrates and niacin as therapeutic options in the treatment of hypertriglyceridemia: a review of the literature. Atherosclerosis. 2015;242:647–656. doi: 10.1016/j.atherosclerosis.2015.06.012. - DOI - PubMed
    1. Binia A, Vargas-Martinez C, Ancira-Moreno M, Gosoniu LM, Montoliu I, Gamez-Valdez E, Soria-Contreras DC, Angeles-Quezada A, Gonzalez-Alberto R, Fernandez S, et al. Improvement of cardiometabolic markers after fish oil intervention in young Mexican adults and the role of PPARalpha L162V and PPARgamma2 P12A. J Nutr Biochem. 2017;43:98–106. doi: 10.1016/j.jnutbio.2017.02.002. - DOI - PubMed

Associated data